Physician profile
Pablo M Arregui
NPI 1043253347
$8,249.20
in general payments reported to CMS, 2019-2025
27 companies · $3,629 in 2025
The $3,629 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $547 · 2021: $501 · 2022: $876 · 2023: $1,214 · 2024: $767 · 2025: $3,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801 · Consulting Fee: $2,778 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.95 |
| Consulting Fee | $2,777.50 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $3,391.91 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
| Glaukos Corporation | $1,930.84 | 2019-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $819.73 | 2019-2023 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Abbvie INC. | $268.22 | 2022-2023 | Durysta, Xen Glaucoma Treatment System |
| Alcon Vision LLC | $267.50 | 2019-2025 | Rocklatan, Acrysof Iq Panoptix Uv Iol, Clareon |
| Aerie Pharmaceuticals, INC. | $197.46 | 2019-2021 | |
| Allergan, INC. | $170.08 | 2020-2022 | |
| New World Medical,INC. | $161.02 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $129.54 | 2021-2023 | |
| Amgen INC. | $108.95 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $91.39 | 2021-2023 | Tepezza |
| Dompe US, INC. | $76.40 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $75.85 | 2020-2024 | |
| Bausch & Lomb Americas INC. | $72.91 | 2022-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Merz Pharmaceuticals, LLC | $71.03 | 2023 | Xeomin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $70.02 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $56.14 | 2019-2020 | |
| Boston Scientific Corporation | $44.08 | 2024 | Wavewriter Alpha Prime 16 |
| Johnson & Johnson Vision Care, INC. | $43.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $43.79 | 2020-2021 | |
| Thea Pharma INC. | $39.15 | 2023-2024 | Iyuzeh |
| Sight Sciences, INC. | $27.37 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Lkc Technologies, INC. | $24.42 | 2025 | |
| Carl Zeiss Meditec, INC. | $19.80 | 2021 | |
| Oyster Point Pharma, INC. | $17.32 | 2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $15.17 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Arregui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.